Experience with viral hepatitis C treatment among people who inject drugs and participate in a methadone substitution treatment program

Authors: L. Krekulová 1,2;  L. Vavrinčíková 1
Authors‘ workplace: Remedis, s. r. o. Praha 1;  IV. Interní klinika, 1. lékařská fakulta, Univerzita Karlova a Všeobecná fakultní nemocnice v Praze 2
Published in: Epidemiol. Mikrobiol. Imunol. 70, 2021, č. 1, s. 18-25
Category: Original Papers


Objectives: Long-term monitoring of the mutual effects of chronic viral hepatitis C (VHC) treatment and tailored addiction treatment. In 2016, the World Health Organization (WHO) published an action plan to eliminate viral hepatitis C globally by 2030. People who inject drugs (PWID) are a key population that needs increased attention and care. Two decades before the announcement of the WHO plan for the global elimination of HCV (hepatitis C virus), the Remedis Medical Facility, where the study was conducted, established a “Comprehensive Care Program for patients with substance use disorders and addictive behaviour”.

Methods: We evaluated all patients who were in the methadone program as of 1 March 2020, regardless of OST duration, OST dosage, age or gender. Their epidemiological and demographic data obtained during a structured clinical interview and laboratory test results were analysed.

Results: Of 24 patients on methadone substitution therapy, 12 (50%) were anti-HCV negative before starting OST. None of them became newly infected with hepatitis C virus (HCV) during OST. The remaining 12 of the study patients were anti-HCV positive. Ten of them have already undergone successful treatment for viral hepatitis. Two patients were re-infected with HCV.

Conclusion: The presented work confirms the high efficacy of chronic VHC treatment among PWID in inducing suitable conditions. We consider combination of HCV infection treatment and targeted tailored addiction treatment as a starting point for achieving control over the HCV epidemic in the Czech Republic, with a possible positive impact on other blood-borne infections related to risky behaviour.


HCV (hepatitis C virus) – VHC (viral hepatitis C) – PWID (People Who Injected Drugs) – OST (opioid substitution treatment) – MTD (methadone) – Remedis, Prague


1.      Global Hepatitis Report 2017 [online]. Geneva: World Health Organization [cit. 2020-02-28]. Dostupný na www: https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf?sequence=1.

2.      Blach S, Zeuzeum S, Manns M, et al. Global prevalence and geno­type distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet [online], 2017;2(3):161–176. [cit. 2020-05-01]. Dostupný na www: https://linkinghub.elsevier.com/retrieve/pii/S2468125316301819.

3.      Stanaway D, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. The Lancet [online], 2016; 388(10049):1081–1088 Dostupný z www: https://linkinghub.elsevier.com/retrieve/pii/S0140673616305797.

4.      Razavi H, Elkhoury C, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology, 2013;57(6):2164–2170. Dostupný z www: http://doi.wiley.com/10.1002/hep.26218.

5.      Buckley GJ, Strom BL. Eliminating the public health problem of hepatitis B and C in the United States: phase one report. Wa­shington, DC: the National Academies Press, 2016.

6.      Zibbel JE, Iqbal KC, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years – Kentucky, Tennessee, Virginia, and West Virgi­nia, 2006-2012. MMWR. Morbidity and mortality weekly report, 2015; 64(17): 453–458.

7.      Suryaprasad AG, White JZ, Xu F, et al. Emerging Epidemic of Hepatitis C Virus Infections Among Young Nonurban Persons Who Inject Drugs in the United States, 2006–2012. Clinical Infectious Diseases [online], 2014; 59(10): 1411-1419. [cit. 2020-04-16]. Dostupný na www: https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciu643.

8.      Guidelines for the screening care and treatment of persons with chronic hepatitis C infection, 2016. Updated version April 2016. Geneva: World Health Organization. ISBN 978-92-4-154961-5. [cit. 2020-04-16]. Dostupný na www: https://apps.who.int/iris/bitstream/handle/10665/205035/9789241549615_eng.pdf?sequence=1.

9.      Hajarizadeh B, Cunningham EB, Reid H, et al. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis [online], 2018;3(11). [cit. 2020-03-31]. Dostupný z www: https://linkinghub.elsevier.com/retrieve/pii/S2468125318303042.

10.    Grebbely J, Larney S, Peacock A, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction [online], 2019;114(1):150–166. [cit. 2020-03-31]. Dostupný z www: http://doi.wiley.com/10.1111/add.14393.

11.    Hagan H, Pouget ER, Des Jarlais DC, et al. Meta-Regression of Hepatitis C Virus Infection in Relation to Time Since Onset of Illicit Drug Injection: The Influence of Time and Place. American Journal of Epidemiology [online], 2008;168(10):1099–1109. [cit. 2020-03-31]. Dostupný na www: https://academic.oup.com/aje/article-lookup/doi/10.1093/aje/kwn237.

12.    Wiessing L, Ferri M, Grady B, et al. Hepatitis C Virus Infection Epi­demiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. PLoS ONE [online], 2014; 9(7): Dostupný na www: https://dx.plos.org/10.1371/journal.pone.0103345.

13.    Global Health Sector Strategy on Viral Hepatitis 2016 - 2021: Towards ending viral hepatitis [online], 2016. In: Geneva: World Health Organization, s. 1–56 [cit. 2020-07-31]. Dostupný na www: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1.

14.    Degenhardt L, Charlson F, Stanaway J, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. The Lancet Infectious Diseases [online], 2016;16(12): 1385–1398. [cit. 2020-03-31]. Dostupný na www: https://linkinghub.elsevier.com/retrieve/pii/S1473309916303255.

15.    Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. The Lancet Global Health [online], 2017;5(12):1192–1207. [cit. 2020-03-31]. Dostupný na www: https://linkinghub.elsevier.com/retrieve/pii/S2214109X17303753.

16.    Edlin BR, Eckhardt BJ, Shu MA, et al. Toward a more accurate estimate of the prevalence of hepatitis C in the United States: a multistage systematic review. Hepatology [online], 2015;62(5):1353–1363. [cit. 2020-07-31]. Dostupný na www: http://doi.wiley.com/10.1002/hep.27978.

17.    Denniston M, Klevens R, Mcquillan G, et al. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008. Hepatology [online], 2012;55(6): 1652–1661. [cit. 2020-07-31]. Dostupný na www: http://doi.wiley.com/10.1002/hep.25556.

18.    Němeček, VJ, Částková P, Fritz A, et al. The 2001 serological survey in the Czech Republic-viral hepatitis. Central European Journal of Public Health, 2003;11(Supplement): S54–61.

19.    Horák J, Střítezký J. Chronické hepatitidy. Praha: Grada, 1999.

20.    Husa P, Střítezký J. Léčba virových hepatitid. Praha: Triton. Levou zadní, 2000.

21.    Mravčík V, Chomynová P, Grohmannová K, et al. Výroční zpráva o stavu ve věcech drog pro Evropské monitorovací středisko pro drogy a drogové závislosti: Česká republika, 2017. Praha: Úřad vlády ČR, 2018. ISBN 978-80-7440-219-7.

22.    Zabransky T, Mravcik V, Korcisova B, et al. Hepatitis C Virus Infection among Injecting Drug Users in the Czech Republic – Prevalence and Associated Factors. European Addiction Research [online], 2006;12(3):151–160. [cit. 2020-03-31]. Dostupný na www: https://www.karger.com/Article/FullText/92117.

23.    Mravčík, V, Chomynová P, Grohmannová K, et al. Výroční zpráva o stavu ve věcech drog v České republice v roce 2018. Praha: Úřad vlády ČR, 2019. ISBN 978-80-7440-237-1.

24.    Mravčík V, Šebáková H. Výskyt virových hepatitid typu B a C u injekčních uživatelů drog v okrese Karviná. Adiktologie, 2002;2(2):19–27. 

25.    Mravčík V. Výskyt VHC u injekčních uživatelů drog: Výsledky studie prováděné mezi klienty nízkoprahových zařízení v letech 2002–2005 [online], 2009. Praha: Úřad vlády České republiky. [cit. 2020-01-27]. Dostupný na www: https://www.drogy-info.cz/data/download/91330/393423/file/5_Vyskyt_VHC_u_injekcnich_uzivatelu_drog_ePubl.pdf.

26.    Mravčík V., Janíková B., Dlouhý P. (ed.) Eliminace virové hepatitidy typu C mezi uživateli drog v České republice: východiska a akční plán na období 2019–2021. Praha: Úřad vlády České republiky, 2019.

27.    Global Health Sector Strategy on Viral Hepatitis 2016 - 2021: Towards ending viral hepatitis [online], 2016. In: Geneva: World Health Organization, p. 1–56 [cit. 2020-07-31]. Dostupný na www: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1.

28.    Mitchell O, Gurakar A. Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review. Journal of Clinical and Translational Hepatology [online], 2015;3(2). [cit. 2020-07-31]. Dostupný na www: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548349/pdf/JCTH-3-140.pdf.

29.    Limketkai, BN, Mehta S, Sutcliffe CG, et al. Relationship of Liver Disease Stage and Antiviral Therapy With Liver-Related Events and Death in Adults Coinfected With HIV/HCV. JAMA [online], 2012:308(4). [cit. 2020-03-31]. Dostupný na www: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2012.7844.

30.    Hickman M, De Angelis D, Vickerman P, et al. Hepatitis C virus treatment as prevention in people who inject drugs. Current Opinion in Infectious Diseases [online], 2015;28(6):576–582. Dostupný na www: http://journals.lww.com/00001432-201512000-00012.

31.    Tucker JD, Meyers K, Best J, et al. The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing. BMC Infectious Diseases [online], 2017;17(S1). [cit. 2020-07-31]. Dostupný na www: http://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2771-4.

32.    Edland-Gryt M, Skatvedt AH. Thresholds in a low-threshold setting: An empirical study of barriers in a centre for people with drug problems and mental health disorders. International Journal of Drug Policy [online], 2013;24(3):257–264. [cit. 2020-07-31]. Dostupný na www: https://linkinghub.elsevier.com/retrieve/pii/S0955395912001193.

33.    Krekulova L, Rehak V, Madrigal N, et al. Genotypic and Epidemiologic Characteristics of Hepatitis C Virus Infections among Recent Injection Drug User and Nonuser Populations. Clinical Infectious Diseases [online], 2001;33(8):1435–1438. [cit. 2020-03-31]. Dostupný na www: https://academic.oup.com/cid/article-lookup/doi/10.1086/323199.

34.    Krekulová L, Řehák V, Oktábec Z, et al. HCV genotype shift occurred over the 15 years in PWIDs in the Czech Republic. Epidemiology, Microbiology, Immunology [online], 2019;68(1): 3–8. [cit. 2020-03-31]. Dostupný na www: https://www.prolekare.cz/casopisy/epidemiologie/2019-1-20/vyvoj-v-zastoupeni-genotypu-hcv-u-injekcnich-uzivatelu-drog-v-ceske-republice-behem-15-let-112615/download?hl=cs.

35.    European Drug Report: Trends and Developments [online]. In: Luxembourg: Publications Office of the European Union. Lisbon: The European Monitoring Centre for Drugs and Drug Addiction, 2016:1–84. [cit. 2020-07-31]. Dostupný na www: https://www.emcdda.europa.eu/system/files/publications/2637/TDAT16001ENN.pdf .

36.    Asselah T, Marcellin P, Schinazi RF. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?. Liver International, 2018;38(2):7–13. DOI: 10.1111/liv.13673. ISSN 14783223. [cit. 2020-03-31]. Dostupný na www: http://doi.wiley.com/10.1111/liv.13673.

37.    Dillon JF, Lazarus JV, Razavi HA. Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatology, Medicine and Policy [online], 2016;1(1). Dostupný na www: http://hmap.biomedcentral.com/articles/10.1186/s41124-016-0011-y.

38.    Platt L, Minozzi S, Reed J, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction, 2018;113(3):545–563. DOI: 10.1111/add.14012. ISSN 09652140. Dostupný na www: http://doi.wiley.com/10.1111/add.14012.

39.    Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. The Lancet Gastroenterology & Hepatology [online], 2018;3(3):153–161 [cit. 2020-08-20]. DOI: 10.1016/S2468-1253(17)30404-1. ISSN 24681253. [cit. 2020-07-31]. Dostupný na www: https://linkinghub.elsevier.com/retrieve/pii/S468125317304041.

40.    Midgard H, Bjǿro B, MÆland, A, et al. Hepatitis C reinfection after sustained virological response. Journal of Hepatology, 2016;64(5):1020–1026. DOI: 10.1016/j.jhep.2016.01.001. ISSN 01688278. Dostupný na www: https://linkinghub.elsevier.com/retrieve/pii/S0168827816000039.

41.    Midgard H, Weir A, Palmateer A, et al. HCV epidemiology in high-risk groups and the risk of reinfection. Journal of Hepato­logy, 2016;65(1):S33–S45. DOI: 10.1016/j.jhep.2016.07.012. ISSN 01688278. Dostupný na www: https://linkinghub.elsevier.com/retrieve/pii/S0168827816303361.

42.    Simmons B. Saleem J, Hill A, et al. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clini­cal Infectious Diseases, 2016;62(6):683–694. DOI: 10.1093/cid/civ948. ISSN 1058-4838. Dostupný na www: https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/civ948.

43. Dore GJ, Greberly J, Altice F, et al. Hepatitis C Virus (HCV) Reinfection and Injecting Risk Behavior Following Elbasvir (EBR)/Grazoprevir (GZR) Treatment in Participants on Opiate Agonist Therapy (OAT): Co-STAR Part B [ABSTRACT 195]. Hepatology, 2017;66(S1):112A. DOI: 10.1002/hep.29500. ISSN 02709139. Dostupný na www: https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.29500.

44.    Page KM, Morris D, Hahn JA, et al. Injection Drug Use and Hepa­titis C Virus Infection in Young Adult Injectors: Using Evidence to Inform Comprehensive Prevention. Clinical Infectious Disea­ses, 2013;57(suppl_2):S32–S38. DOI: 10.1093/cid/cit300. ISSN 1537-6591. Dostupný na www: http://academic.oup.com/cid/article/57/suppl_2/S32/397297/Injection-Drug-Use-and-Hepatitis-C-Virus-Infection.

45.    Heffernan A, Cooke GS, Nayagam S, et al. Scaling up prevention and treatment towards the elimination of hepatitis C: a glo­bal mathematical model. The Lancet [online], 2019;393(10178): 1319–1329. [cit. 2020-07-31]. Dostupný na www: https://linkinghub.elsevier.com/retrieve/pii/S0140673618322773.

46.    Martin NK, Vickerman P, Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. Journal of Theo­retical Biology [online], 2011;274(1):58–66. [cit. 2020-07-31]. Dostupný na www: https://linkinghub.elsevier.com/retrieve/pii/S0022519311000038..

Hygiene and epidemiology Medical virology Clinical microbiology

Article was published in

Epidemiology, Microbiology, Immunology

Issue 1

2021 Issue 1

Most read in this issue
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account